

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier		
Trade name	:	Orbifloxacin / Posaconazole / Mometasone Formulation
1.2 Relevant identified uses of t	the s	substance or mixture and uses advised against
Use of the Sub- stance/Mixture	:	Veterinary product
Recommended restrictions on use	:	Not applicable
1.3 Details of the supplier of the	e saf	fety data sheet
Company	:	MSD Kilsheelan Clonmel Tipperary, IE
Telephone	:	353-51-601000
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2H319: CausesLong-term (chronic) aquatic hazard, Cat-
egory 2H411: Toxic to

H319: Causes serious eye irritation. H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION	(EC)	No 1272/20	08)
Hazard pictograms	:		¥2
Signal word	:	Warning	·
Hazard statements	:	H319	Causes serious eye irritation.



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
		H411	Toxic to aquatic life with long lasting effects.
Preca	utionary statements	: Prevention	
	-	P264	Wash skin thoroughly after handling.
		P273	Avoid release to the environment.
		P280	Wear eye protection/ face protection.
		Response:	
		P337 + P31	3 If eye irritation persists: Get medical advice/ attention.
		P391	Collect spillage.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
onemical name	EC-No.	Classification	(% w/w)
	Index-No.		(/0 11/11)
	Registration number		
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 1 - < 3
-	171000 10 0		
Posaconazole	171228-49-2	Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kidney, Liv- er, Nervous system, Reproductive organs) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 0.1 - < 0.25
		M-Factor (Acute	



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016		
			aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1		
Mome	etasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	>= 0.1 - < 0.25	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed



Version 2.19	Revision Date: 28.09.2024		9S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Risks		:	Causes serious e	eye irritation.
4.3 Indica Treat	-	meo		d special treatment needed ically and supportively.
near		•	Treat symptomat	
SECTION	N 5: Firefighting meas	sur	es	
5.1 Exting	uishing media			
Suita	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
5.2 Specia	al hazards arising from	the	substance or m	ixture
Speci fightir	ific hazards during fire-	:	Exposure to com	bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides	
5.3 Advic	e for firefighters			
	ial protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.
Speci ods	ific extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. Iged containers from fire area if it is safe to do

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro-
	tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
-		Prevent further leakage or spillage if safe to do so.
		Prevent spreading over a wide area (e.g. by containment or oil
		barriers).



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
			ose of contaminated wash water. s should be advised if significant spillages ained.
6.3 Method	ds and material for co	ontainment and clear	ning up
Metho	ds for cleaning up	For large spills, ment to keep m be pumped, sto Clean up remain bent. Local or nationa posal of this ma employed in the mine which regu Sections 13 and	ert absorbent material. provide dyking or other appropriate contain- aterial from spreading. If dyked material can re recovered material in appropriate container. ning materials from spill with suitable absor- al regulations may apply to releases and dis- terial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable. d 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	<i>,</i>	
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaus ventilation.	st
Advice on safe handling	 Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safe practice, based on the results of the workplace exposure as sessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to 	s-
Hygiene measures	 environment. If exposure to chemical is likely during typical use, provide flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash conta nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 	ımi- f t,



	Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
--	-----------------	---------------------------	-----------------------------	---

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	:	Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases
7.3 Specific end use(s)		

: No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Specific use(s)

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
White mineral oil (petroleum)	8042-47-5	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
Orbifloxacin	113617-63- 3	TWA	0.2 mg/m3 (OEB 2)	Internal
Posaconazole	171228-49- 2	TWA	300 µg/m3 (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	nation: Skin		
		Wipe limit	10 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Hand	protection	potential for c aerosols.	lirect contact to the face with dusts, mists, or
Material		: Chemical-res	istant gloves
Remarks Skin and body protection		Additional bo task being pe posable suits	or laboratory coat. dy garments should be used based upon the rformed (e.g., sleevelets, apron, gauntlets, dis-) to avoid exposed skin surfaces. ate degowning techniques to remove potentially
Resp	Respiratory protection : If adequate local exhaust ventilation is not ava sure assessment demonstrates exposures out ommended guidelines, use respiratory protect Equipment should conform to I.S. EN 14387		
Fil	lter type	: Combined pa	rticulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available



Ver: 2.19	sion Ə	Revision Date: 28.09.2024		S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
	Decom	nposition temperature	:	No data available	9
	рН		:	No data available	9
	Viscos Vise	ity cosity, kinematic	:	No data available	9
		lity(ies) ter solubility	:	No data available	9
		on coefficient: n- I/water	:	Not applicable	
	Vapou	r pressure	:	No data available	9
	Relativ	e density	:	No data available	9
	Densit	у	:	No data available	9
	Relativ	ve vapour density	:	No data available	9
		e characteristics ticle size	:	Not applicable	
9.2	Other i	nformation			
	Explos	lives	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapo	ration rate	:	No data available	2

SECTION 10: Stability and reactivity

10.1 Reactivity Not classified as a reactivity haz	ard.	
10.2 Chemical stability Stable under normal conditions.		
10.3 Possibility of hazardous react	lions	
Hazardous reactions	: Can react with strong oxidizing agents.	
10.4 Conditions to avoid		
Conditions to avoid	: None known.	
10.5 Incompatible materials Materials to avoid	: Oxidizing agents	



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Pr	oduct:	

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Remarks: No significant adverse effects were reported No mortality observed at this dose.
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Remarks: No significant adverse effects were reported
Components:		
Orbifloxacin:		
Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 200 mg/kg Application Route: Intramuscular
		LD50 (Mouse): 500 mg/kg Application Route: Intramuscular
		LD50 (Rat): 233 mg/kg Application Route: Intravenous
		LD50 (Mouse): 250 mg/kg



ersion 19	Revision Date: 28.09.2024		0S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
			Application Route	e: Intravenous
Posa	conazole:			
Acute oral toxicity		:	LD50 (Rat): > 5,0	00 mg/kg
			LD50 (Mouse): >	3,000 mg/kg
Acute	e dermal toxicity	:	LD50 (Rat): > 2,0	00 mg/kg
Mom	etasone:			
	e oral toxicity	:	LD50 (Rat): > 2,0	00 mg/kg
			LD50 (Mouse): >	2,000 mg/kg
Acute	e inhalation toxicity	:	Exposure time: 4 Test atmosphere:	h
			LC50 (Mouse): > Exposure time: 4 Test atmosphere:	h
	e toxicity (other routes of nistration)	:	LD50 (Rat): 300 r Application Route Symptoms: Breat	: Subcutaneous
Skin	corrosion/irritation			
Not c	lassified based on availa	ble	information.	
Prod				
Spec Resu		:	Rabbit Mild skin irritation	
Com	ponents:			
Orbif	loxacin:			
	ies	:	Rabbit	
Spec	100		Draize Test	
Meth	od	÷		
	od	:	No skin irritation	
Meth Resu	od	:		
Meth Resu	od It I conazole: ies	:		
Meth Resu Posa Spec Resu	od It I conazole: ies	:	No skin irritation Rabbit	
Meth Resu Posa Spec Resu	od It iconazole: ies It etasone: ies	:	No skin irritation Rabbit	



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

Serious eye damage/eye irritation

Causes serious eye irritation.

Product:

Species	:	Rabbit
Result	:	Mild eye irritation

Components:

Orbifloxacin:

Species	:	Rabbit
Method	:	Draize Test
Result	:	Mild eye irritation

Posaconazole:

Species	:	Rabbit
Result	:	Mild eye irritation

Mometasone:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Product:

Test Type	:	Magnusson-Kligman-Test
Exposure routes	:	Dermal
Result	:	Not a skin sensitizer.

Components:

Orbifloxacin:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Posaconazole:

Test Type	:	Magnusson-Kligman-Test
Exposure routes	:	Skin contact
Species	:	Guinea pig



Version 2.19	Revision Date: 28.09.2024		S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Resu	ılt	:	negative	
Test	netasone: Type osure routes	:	Maximisation	Fest
Spec	cies essment Ilt		Guinea pig Does not cause skin sensitisation. negative The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.	
	n cell mutagenicity classified based on ava	ailable	information.	
<u>Com</u>	ponents:			
Orbi	floxacin:			
Geno	otoxicity in vitro	:	Test Type: Bao Result: equivo	cterial reverse mutation assay (AMES) cal
			Test Type: Mo Result: positive	use Lymphoma e
				romosomal aberration łuman lymphocytes e
Geno	otoxicity in vivo	:	Test Type: Mic Species: Mous Cell type: Bon Application Ro Result: negativ	se e marrow ute: Intraperitoneal injection
			Ū	scheduled DNA synthesis assay r cells
			Result: negativ	
	n cell mutagenicity- As- ment	- :	Weight of evid cell mutagen.	ence does not support classification as a germ
Posa	aconazole:			
Geno	otoxicity in vitro	:	Test Type: Bac Result: negativ	cterial reverse mutation assay (AMES) /e
			Test Type: Ch Result: negativ	romosomal aberration /e
Geno	otoxicity in vivo	:	Test Type: Mic	cronucleus test



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
		Species: Mo Cell type: Bo Application F Result: nega	one marrow Route: Intravenous
Mome	etasone:		
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES) ative
			Chromosomal aberration : Chinese hamster lung cells ative
		•••	Chromosomal aberration : Chinese hamster ovary cells ive
		Test Type: N Result: nega	Aouse Lymphoma ative
Geno	toxicity in vivo	: Test Type: N Species: Mo Application F Result: nega	Route: Oral
		Test Type: C Species: Ra Cell type: Bo Result: nega	one marrow
		Test Type: u Species: Ra Cell type: Liv Result: nega	ver cells
Germ sessn	cell mutagenicity- As- nent	: Weight of ev cell mutager	idence does not support classification as a germ
	nogenicity assified based on availa	able information.	
<u>Com</u>	oonents:		
Orbif	loxacin:		
	cation Route sure time EL	: Rat : Oral : 2 Years : 200 mg/kg b : negative	ody weight

Species

13 / 28

: Mouse



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016				
		: Oral : 2 Years : 200 mg/kg bo : negative	2 Years 200 mg/kg body weight				
Posa	conazole:						
	cation Route sure time It	: Rat : oral (feed) : 2 Years : positive : The mechanis	sm or mode of action is not relevant in humans.				
Species:MouseApplication Route:OralExposure time:2 YearsResult:positiveRemarks:The mechanism or mode of action is		sm or mode of action is not relevant in humans.					
Mom	etasone:						
	cation Route sure time	: Rat : Inhalation : 2 Years : 0.067 mg/kg l : negative	body weight				
	cation Route sure time	: Mouse : Inhalation : 19 Months : 0.160 mg/kg l : negative	body weight				
Renr	oductive toxicity						
•	lassified based on avail	lable information.					
Com	ponents:						
	loxacin: ts on fertility	Species: Rat Application R General Toxic	city - Parent: NOAEL: 50 mg/kg body weight nic Development: NOAEL: 50 mg/kg body				
Effec ment	ts on foetal develop-	Species: Rat Application R Embryo-foeta	nbryo-foetal development oute: Oral I toxicity: LOAEL: 333 mg/kg body weight ratogenic effects, Embryotoxic effects and ad-				

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
		verse effects of ternally toxic of	on the offspring were detected only at high ma- doses
		Species: Rabl Application Ro General Toxic Embryo-foeta Result: No eff toxic effects a	bute: Oral bity Maternal: NOAEL: 20 mg/kg body weight I toxicity: NOAEL: 60 mg/kg body weight ects on early embryonic development, Embryo- nd adverse effects on the offspring were detect- h maternally toxic doses, Reduced maternal
•	roductive toxicity - As- ment	: Some evidend animal experi	ce of adverse effects on development, based on ments.
Pos	aconazole:		
Effe	cts on fertility	Species: Rat, General Toxic	ity - Parent: NOAEL: 180 mg/kg body weight o effects on mating performance
		Species: Rat, General Toxic	ity - Parent: NOAEL: 45 mg/kg body weight o effects on mating performance
Effe men	cts on foetal develop- t	Species: Rat, Application Ro Developmenta	
		Species: Rabl	al Toxicity: LOAEL: 40 mg/kg body weight
	roductive toxicity - As-	: Some evidend animal experi	ce of adverse effects on development, based on ments.



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Мо	metasone:		
Effe	ects on fertility	Fertility: NOAEL: Symptoms: Redu weight	ty e: Subcutaneous 0.015 mg/kg body weight uced embryonic survival, Reduced foetal s on fertility, Effect on reproduction capacity
Effects on foetal develop- : ment		Species: Mouse Application Route Embryo-foetal to	yo-foetal development e: Subcutaneous xicity: LOAEL: 0.06 mg/kg body weight oxic effects., Teratogenicity and developmen-
		Species: Rat Application Rout	xicity: LOAEL: 0.3 mg/kg body weight
		Species: Rabbit Application Route Embryo-foetal to	yo-foetal development e: Dermal xicity: LOAEL: 0.15 mg/kg body weight oetal toxicity, Malformations were observed.
		Species: Rat Application Rout	yo-foetal development e: Subcutaneous xicity: LOAEL: 0.15 mg/kg body weight n newborn
		Species: Rabbit Application Rout Embryo-foetal to	yo-foetal development e: Oral xicity: LOAEL: 0.7 mg/kg body weight foetal toxicity, Malformations were observed.
	productive toxicity - As- sment	animal experime	f adverse effects on development, based on nts., Some evidence of adverse effects on and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks

: Based on available data, the classification criteria are not met.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

STOT - repeated exposure

Not classified based on available information.

Components:

Posaconazole: Exposure routes Target Organs Assessment	Ingestion Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system Causes damage to organs through prolonged or repeated exposure.	
Mometasone: Exposure routes Target Organs Assessment	inhalation (dust/mist/fume) Immune system, Liver, Kidney, Skin May cause damage to organs through prolonged or repea exposure.	ated
Repeated dose toxicity		
Components:		
Orbifloxacin: Species NOAEL	Rat 20 mg/kg	
LOAEL Application Route Exposure time Target Organs	80 mg/kg Oral 3 Months Testis, Liver, Kidney, spleen	

Species NOAEL LOAEL Application Route Exposure time Target Organs Symptoms Remarks	: : :	Juvenile dog 50 mg/kg 250 mg/kg Oral 14 Days Heart, Bone Gastrointestinal disturbance mortality observed
Species NOAEL LOAEL Application Route		Juvenile dog 2 mg/kg 3 mg/kg Oral



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
	sure time et Organs arks	: 90 Days : Bone : No significant	adverse effects were reported
		: Dog : 37.5 mg/kg : Oral : 30 Days	
Expo	EL	: Cat : 7.5 mg/kg : 22.5 mg/kg : Oral : 1 Months : Gastrointestin	nal disturbance
Spec LOAI Appli Expo		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal gland	l, Lungs, Heart, Liver, spleen, Kidney, Ovary
Expo		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lymphoi	Brain, small intestine, Adrenal gland, Spinal d tissue
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrow	, Adrenal gland, Lymph nodes, Blood
Expo			l, Bone marrow, Kidney, Nervous system, us gland, Testis, lymphoid tissue
Expo		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastro	intestinal tract, spleen
Spec LOAI		: Monkey : 8 mg/kg	



Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024		DS Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Expos	cation Route sure time t Organs	:	Intravenous 1 Months Cardio-vascular	system, Lungs, Adrenal gland, Blood
Speci NOAE LOAE Applic Expos	EL EL sation Route sure time of Organs es		Rat 0.005 mg/kg 0.3 mg/kg Oral 30 d Lymph nodes, Li Dog 0.5 mg/kg	ver, Adrenal gland, Skin, thymus gland
Expos Targe Speci		::	Oral 30 d Lymph nodes, Li Rat	ver, Adrenal gland, Skin, thymus gland
Expos	EL cation Route sure time t Organs	:	0.00013 mg/l inhalation (dust/r 90 d Adrenal gland, L Kidney, Liver, thy	ungs, Lymph nodes, spleen, Bone marrow,
Expos			Dog 0.0005 mg/l inhalation (dust/r 90 d Adrenal gland, L Kidney, thymus g	ungs, Lymph nodes, spleen, Bone marrow,

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

Experience with human exposure

Components:		
Orbifloxacin:		
Ingestion	:	Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
Posaconazole:		
Ingestion	:	Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance
Mometasone:		
Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper res- piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching
Further information		
Components:		
Mometasone:		
Remarks	:	Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

Posaconazole:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l



Orbifloxacin / Posaconazole / Mometasone Formulation

Versior 2.19	n	Revision Date: 28.09.2024		S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
				Exposure time: 72 Method: OECD Te	
	-Facto ity)	or (Acute aquatic tox-	:	1	
Τc	oxicity	to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
	oxicity ity)	to fish (Chronic tox-	:	NOEC: 0.206 mg/ Exposure time: 33 Species: Pimepha Method: OECD Te	3 d ales promelas (fathead minnow)
aq		to daphnia and other invertebrates (Chron- y)	:	Method: OECD Te	l d magna (Water flea)
	-Facto xicity)	r (Chronic aquatic	:	1	
M	ometa	asone:			
Τc	oxicity	to fish	:	Exposure time: 96	ryllina (Silverside)): 0.11 mg/l 5 h city at the limit of solubility
				Exposure time: 7	n variegatus (sheepshead minnow)): > 5 mg/l d city at the limit of solubility
	-	to daphnia and other invertebrates	:	Exposure time: 48 Method: OECD Te	
				EC50 (Americamy Exposure time: 96 Method: US-EPA Remarks: No toxid	3 h
	oxicity ants	to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD Te	
To	oxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 3	

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Orbifloxacin / Posaconazole / Mometasone Formulation

Versio 2.19	n	Revision Date: 28.09.2024		0S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
					ration inhibition est Guideline 209 city at the limit of solubility
					h
	oxicity city)	v to fish (Chronic tox-	:		
а		to daphnia and other invertebrates (Chron- ty)	:	Method: OECD T	a magna (Water flea)
	/I-Fact	or (Chronic aquatic	:	100	
	• •	tence and degradabil	ity		
<u>c</u>	Compo	onents:			
Р	osaco	onazole:			
В	Biodeg	radability	:	Result: Not readil Biodegradation: 4 Exposure time: 28 Method: OECD T	50 %
S	Stability	/ in water	:	-	life (DT50): > 30 d est Guideline 111
N	lomet	asone:			
		radability	:	Result: Not readil Biodegradation: 4 Exposure time: 28 Method: OECD T	50 %
S	Stability	/ in water	:	Hydrolysis: 50 %(Method: OECD T	(12 d) est Guideline 111
12.3 E	Bioaco	umulative potential			
C	compo	onents:			

Components:

Posaconazole:



Version 2.19	Revision Date: 28.09.2024		DS Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Bioaccumulation		:	Bioconcentration	s macrochirus (Bluegill sunfish) factor (BCF): 20 ēst Guideline 305
	ion coefficient: n- ol/water	:	log Pow: 4.15	
Mom	etasone:			
Bioac	ccumulation	:	Bioconcentration	s macrochirus (Bluegill sunfish) factor (BCF): 107.1 est Guideline 305
	ion coefficient: n- ol/water	:	log Pow: 4.68	
12.4 Mobi	ility in soil			
Com	ponents:			
Posa	conazole:			
Distri	Distribution among environ- mental compartments		log Koc: 5.52	
Distri	etasone: bution among environ- al compartments	:	log Koc: 4.02	
12.5 Resu	Its of PBT and vPvB a	isse	ssment	
Prod	uct:			
	ssment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Endo	ocrine disrupting prop	ertie	es	
Prod	uct:			
-	ssment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
	r adverse effects ata available			

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations.



Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
2.19		441602-00021	Date of first issue: 06.01.2016
Conta	minated packaging	are not product Waste codes s discussion with Do not dispose : Empty containe dling site for re	ne European Waste Catalogue, Waste Codes t specific, but application specific. hould be assigned by the user, preferably in the waste disposal authorities. e of waste into sewer. ers should be taken to an approved waste han- cycling or disposal. e specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN	number	or ID	number
---------	--------	-------	--------

ADN	:	UN 3082	
ADR	:	UN 3082	
RID	:	UN 3082	
IMDG	:	UN 3082	
ΙΑΤΑ	:	UN 3082	
14.2 UN proper shipping name			
ADN	:	ENVIRONMENTALL N.O.S. (Mometasone, Posac	Y HAZARDOUS SUBSTANCE, LIQUID, conazole)
ADR	:	ENVIRONMENTALL N.O.S. (Mometasone, Posad	Y HAZARDOUS SUBSTANCE, LIQUID, conazole)
RID	:	ENVIRONMENTALL N.O.S. (Mometasone, Posad	Y HAZARDOUS SUBSTANCE, LIQUID, conazole)
IMDG	:	ENVIRONMENTALL N.O.S. (Mometasone, Posad	Y HAZARDOUS SUBSTANCE, LIQUID, conazole)
ΙΑΤΑ	:	Environmentally haza (Mometasone, Posad	ardous substance, liquid, n.o.s. conazole)
14.3 Transport hazard class(es)			
		Class	Subsidiary risks
ADN	:	9	
ADR	:	9	
RID	:	9	
IMDG	:	9	
ΙΑΤΑ	:	9	
14.4 Packing group			



Orbifloxacin / Posaconazole / Mometasone Formulation

Versior 2.19	n Revision Date: 28.09.2024	SDS Number: 441602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Pa Cl Ha	DN acking group assification Code azard Identification Number ubels	: III : M6 : 90 : 9	
Pa Cl Ha La	DR acking group assification Code azard Identification Number abels annel restriction code	: III : M6 : 90 : 9 : (-)	
CI Ha	D acking group assification Code azard Identification Number abels	: III : M6 : 90 : 9	
Pa La	IDG acking group ıbels nS Code	: III : 9 : F-A, S-F	
Pa aii Pa Pa	TA (Cargo) acking instruction (cargo rcraft) acking instruction (LQ) acking group abels	: 964 : Y964 : III : Miscellaneou	s
Pa ge Pa Pa	TA (Passenger) acking instruction (passen- er aircraft) acking instruction (LQ) acking group abels	: 964 : Y964 : III : Miscellaneou	S
14.5 Ei	nvironmental hazards		
Er	DN nvironmentally hazardous	: yes	
	DR nvironmentally hazardous	: yes	
RI Er	D nvironmentally hazardous	: yes	
	IDG arine pollutant	: yes	
	TA (Passenger) nvironmentally hazardous	: yes	
	TA (Cargo) nvironmentally hazardous	: yes	



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

of dangerous chemicals

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import	:	Not applicable

REACH - List of substances subject to authorisation : Not applicable (Annex XIV) Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

The components of this product are reported in the following inventories:

AICS	: not dete	rmined
DSL	: not dete	rmined



Version 2.19	Revision Date: 28.09.2024		9S Number: 1602-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
IEC	SC	:	not determined	
A Chem	emical safety assessmen ical Safety Assessment ha	s no	ot been carried out	
SECTIO	ON 16: Other information	on		
Oth	er information	:		ges have been made to the previous version the body of this document by two vertical
Ful	I text of H-Statements			
H3 ²	19	:	Causes serious e	ve irritation.
H36	60Df	:		unborn child. Suspected of damaging fertili-
H36		:		naging the unborn child.
H37	72	:		o organs through prolonged or repeated
H37	73	:	exposure if swalld May cause damage exposure if inhale	ge to organs through prolonged or repeated
H4(00	:	Very toxic to aqua	
H41	10	:	Very toxic to aqua	atic life with long lasting effects.
Ful	I text of other abbreviation	ons		
Αqι	atic Acute	:	Short-term (acute	
	atic Chronic	:	Long-term (chron	ic) aquatic hazard
	e Irrit.	:	Eye irritation	-14
Rep	or. OT RE	÷	Reproductive toxi	
	DEL	:		an toxicity - repeated exposure emical Agents and Carcinogens with Occu-
		•		Elimit Values - Code of Practice, Schedule 1
IE C	DEL / OELV - 8 hrs (TWA)	:		osure limit value (8-hour reference period)
Wa Roa ing tion of t Eur ass	terways; ADR - Agreeme ad; AIIC - Australian Invent of Materials; bw - Body w (EC) No 1272/2008; CMF he German Institute for St opean Chemicals Agency; ociated with x% response;	nt o tory eigh R - 0 and EL	concerning the Inte of Industrial Chern nt; CLP - Classifica Carcinogen, Mutag lardisation; DSL - C-Number - Europe x - Loading rate as	tional Carriage of Dangerous Goods by Inland ernational Carriage of Dangerous Goods by hicals; ASTM - American Society for the Test- tion Labelling Packaging Regulation; Regula- gen or Reproductive Toxicant; DIN - Standard Domestic Substances List (Canada); ECHA - ean Community number; ECx - Concentration sociated with x% response; EmS - Emergen- Substances (Japan); ErCx - Concentration as-

sociated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization;



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441602-00021	Date of first issue: 06.01.2016

KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixtur	Classification procedure:	
Eye Irrit. 2	H319	Based on product data or assessment
Aquatic Chronic 2	H411	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN